SLS
SELLAS Life Sciences Group, Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.14
+3.04%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$8.89
From 52W high−40.88%
Volume5.36M
Market cap$1.85B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$8.89
From 52W high
−40.88%
Volume
5.36M
Market cap
$1.85B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−67.3x
P/E (TTM)
—
RSI (14)
36.0
MomentumView details →
1D Return
+3.04%
YTD Return
+134.62%
SummaryUpdated Jun 1, 2026
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) is a late-stage biopharmaceutical company founded in 2012 and headquartered in New York, New York. The company went public in 2008 and focuses on developing novel cancer immunotherapies for various cancer indications. SELLAS operates as a clinical-stage biotechnology company with no current commercial products, dedicating its resources to advancing multiple cancer treatment candidates through clinical trials.
Similar companies
Latest newsMore news →
SELLAS Life Sciences announced that it will present completed Phase 2 data on SLS009 combined with azacitidine and venetoclax in relapsed or refractory AML at the ASH Annual Meeting.7h ago3D Medicines, Inc. said the phase III REGAL trial of 3D189 (Galinpepimut-S) for acute myeloid leukemia reached its prespecified 80-death event threshold, triggering final analysis.6d ago